Faron Pharmaceuticals Oy (LSE:FARN) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 11, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Faron Pharmaceuticals Oy's float shares is 0.00 Mil. Faron Pharmaceuticals Oy's total shares outstanding is 86.68 Mil. Faron Pharmaceuticals Oy's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Faron Pharmaceuticals Oy's Insider Ownership is 6.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Faron Pharmaceuticals Oy's Institutional Ownership is 5.43%.

Faron Pharmaceuticals Oy Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Faron Pharmaceuticals Oy's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	86.68
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines